Home › Gastrointestinal Stromal Tumors › Washington
Gastrointestinal Stromal Tumors clinical trials in Washington, DC
4 studies for Gastrointestinal Stromal Tumors are looking for participants at sites in and around Washington (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
RecruitingPhase 3
- GSK Investigational Site, Washington D.C.
A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)
RecruitingPhase 3
- GSK Investigational Site, Bethesda · 7 mi away
Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis
RecruitingObservational study
- National Institutes of Health Clinical Center, Bethesda · 7 mi away
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
RecruitingPhase 3
- MedStar Washington Hospital Center, Washington D.C.
Gastrointestinal Stromal Tumors trials in other cities
- Miami, FL8 studies
- New York City, NY7 studies
- Boston, MA7 studies
- Philadelphia, PA6 studies
- Houston, TX6 studies
- San Diego, CA5 studies
- Portland, OR5 studies
- Nashville, TN5 studies
- Omaha, NE5 studies
- Jacksonville, FL4 studies
- Rochester, MN4 studies
- Dallas, TX4 studies
Other studies in Washington
- Cancer (all types)58 studies
- Non-Small Cell Lung Cancer55 studies
- Breast Cancer46 studies
- Metastatic Cancer43 studies
- Lung Cancer41 studies
- Prostate Cancer38 studies
- Obesity33 studies
- Colorectal Cancer29 studies
- Cardiovascular Disease28 studies
- Bladder Cancer26 studies
- Acute Myeloid Leukemia24 studies
- Ovarian Cancer23 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.